"Skin booster" is on clinic menus, serum bottles and short-form videos, and it sounds like one thing. It is several. The word covers injectable hyaluronic acid, DNA fragments from fish milt, exosome preparations, collagens and plain topical serums, which is why readers asking "do skin boosters work?" get answers that contradict each other: they are asking about different substances. This page sorts the category by what is actually in it, counts the literature, and sets out what US regulators have and have not approved. It does not recommend any product or procedure; an injectable is a medical decision for a qualified clinician.
The word is not a category
No regulator we found uses "skin booster" as a legal category. In the US, an injectable is regulated as a device or a drug depending on what it is, and a topical product is usually a cosmetic. The same two words sit on all of them. The substances sold under the name, in the order this site covers them:
| What is sold as a skin booster | What it is | Our page |
|---|---|---|
| Injectable hyaluronic acid (HA) | A sugar polymer that binds water; the same family as HA fillers | Peptides vs hyaluronic acid covers HA as a topical ingredient |
| PDRN | Purified DNA fragments, usually from salmon or trout milt; not a peptide | PDRN |
| Polynucleotides | Longer DNA chains from the same sources | Polynucleotides for skin |
| Exosomes | Tiny vesicles released by cells, sold as extracts of cell cultures (what shop labels actually declare) | — |
| Collagen injectables | Recombinant or animal-derived collagen | — |
| Topical "booster" serums | Cosmetics; contents vary product by product | e.g. our COSRX 6 Peptide Skin Booster Serum analysis |
The practical consequence: a result for one row says nothing about another. A trial of an HA gel is not evidence for a DNA injectable, and neither is evidence for a serum. Collagen stimulators are a further class again: poly-L-lactic acid, for example, is approved in the US as its own device, and its separate trial and adverse-event record is read on our Sculptra explainer. The two best-known stimulators are compared on approvals, particles and FDA reports in our Sculptra-and-Radiesse comparison.
Injectable and topical are different questions
Clinics describe a booster injection as placing small amounts of material in or just under the skin, across an area, to improve texture, fine lines or hydration rather than to add volume. That is a procedure with a device, a practitioner and a regulatory file (or the lack of one).
A serum with "booster" on the label is a cosmetic that has to get its ingredients through the skin's outer layer on its own. Most of the headline booster materials are very large molecules. The PDRN used in the clinical trials is at least 50,000 daltons, about 100 times the roughly 500-dalton rule of thumb for what can cross intact skin; the human-collagen ingredient in one booster serum we analysed copies a chain of 99,369 daltons. The rule of thumb is a rough guide, not a law, but it is why the injected and the topical versions of the "same" booster should never be read as one product.
What US regulators have approved
We searched FDA's premarket-approval (PMA) database for approvals whose statement mentions skin smoothness or skin quality, and for the trade names most often used for boosters, on 27 September 2026.
- SKINVIVE by Juvederm is the only approval we found for a booster-type indication. FDA approved it on 11 May 2023 (PMA P110033, supplement S059), "indicated for intradermal injection to improve facial skin smoothness of the cheeks in adults over the age of 21". It is a hyaluronic-acid gel from the same approval file as the Juvederm filler range. The search for the word "smoothness" in approval statements returned no other product. On 11 June 2026 FDA added a second indication, reducing neck lines (supplement S099); our SKINVIVE label and FDA-record analysis reads both pivotal trials and the adverse-event reports.
- No PDRN or polynucleotide injectable had a 510(k) clearance or a PMA approval on 24 September 2026, when we searched for polynucleotide, polydeoxyribonucleotide, salmon DNA and Rejuran (the detail is on our PDRN page). The brand's leave-on serum is a separate, cosmetic product, and what its label declares is set out in our reading of the Turnover Ampoule.
- No approval record under the name Profhilo, a hyaluronic-acid booster sold in the UK and Europe, was in the PMA database on 27 September 2026.
- Topical booster serums are cosmetics and need no FDA approval before sale.
An absence in FDA's databases means a product is not authorised for sale as that device in the US. It is not a finding about safety, and products can be authorised elsewhere.
No approved skin device is a peptide either: every FDA approval whose generic name contains "synthetic peptide" is a bone graft, as our census of peptide injections for skin records.
What the literature holds
On 27 September 2026, Europe PMC's copy of MEDLINE held 186 records using "skin booster", "skin boosters", "skinbooster" or "skinboosters". (PubMed's own search was unavailable that morning, so these counts come from Europe PMC.) The growth is recent: 2 records in 2015, 55 in 2025.
Eleven of the 186 carry the randomized-controlled-trial publication type. Read one by one, they test at least six different materials:
| Material tested under the "skin booster" name | Example (year, PMID) |
|---|---|
| Hyaluronic acid (including in combination with toxin and filler) | 2019, 31334927; 2020, 31769596; 2025, 40304039 |
| Poly-D,L-lactic acid (PDLLA), comparing injection depths for pain | 2026, 41501430 |
| Polynucleotide filler, comparing injection pain | 2026, 41361144 |
| Exosomes (skin barrier; surgical scars) | 2026, 42403177; 2026, 41748500 |
| Recombinant humanised type III collagen | 2026, 42087486 |
| Human acellular dermal matrix particles | 2026, 41828422 |
Two of those trials measured injection pain, not skin outcomes. The set is small, recent and spread across materials that have nothing in common chemically, which is exactly what a marketing term produces when it is used as a search term.
Four of the 186 records are retracted, among them a 2024 review titled "Skin boosters: Definitions and varied classifications" (PMID 38481069) and a 2022 study of a polynucleotide product for the mid-face (PMID 34791770). The field's attempt to define itself is one of its retracted papers. Our polynucleotides page explains why every count on this site now runs the retraction filter.
Reading a booster claim
Three questions sort most of what readers meet:
- What is the material? HA, a DNA fragment, exosomes, collagen or a serum? The answer decides which evidence applies. If a clinic or a label will not name it, that is the finding. For exosomes sold for thinning hair, our exosome hair-loss census counts the trials and the registry.
- Injected or applied? The randomized trials above are injection trials. A serum inherits none of them.
- Authorised where? A product approved in Korea or carrying a European mark is not thereby approved in the US, and the reverse. For DNA-fragment injectables, the US record is empty as of September 2026.
The DNA-fragment end of the category is covered in depth on our PDRN and polynucleotides pages, and the serum end on PDRN serum. For peptide ingredients with a topical trial record, see what peptides do for skin.